Overview

Senolytics to Improve Osteoporosis Therapy

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.
Phase:
Phase 2
Details
Lead Sponsor:
Odense University Hospital
Collaborators:
Novo Nordisk A/S
Odense Patient Data Explorative Network
Treatments:
Dasatinib
Niacinamide
Quercetin